Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Kymera Therapeutics reported a quarterly loss of $0.9 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.71, marking a surprise of -26.76% [1] - The company's revenues for the quarter ended September 2025 were $2.76 million, missing the Zacks Consensus Estimate by 89.6%, and down from $3.74 million a year ago [2] - The stock has increased approximately 48.5% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Kymera Therapeutics has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $20.64 million, and for the current fiscal year, it is -$3.28 on revenues of $80.83 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Kymera Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Kymera's stock performance [5][6]